| Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State (NCT07242664) | Gan and Lee Pharmaceuticals, USA | 2025-10-13 |
| Comparison Study of Insulin GZR4 With Insulin Degludec (NCT07146347) | Gan and Lee Pharmaceuticals, USA | 2025-08-15 |
| Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants (NCT06737042) | Gan and Lee Pharmaceuticals, USA | 2025-02-24 |
| A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects (NCT06670209) | Gan and Lee Pharmaceuticals, USA | 2024-10-30 |
| Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment (NCT06547502) | Gan and Lee Pharmaceuticals, USA | 2024-07-03 |
| A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD (NCT06558708) | Gan and Lee Pharmaceuticals, USA | 2024-06-28 |
| A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM (NCT06199505) | Gan and Lee Pharmaceuticals, USA | 2023-11-21 |
| A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus (NCT06256549) | Gan and Lee Pharmaceuticals, USA | 2023-08-09 |
| A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes (NCT06553248) | Gan and Lee Pharmaceuticals, USA | 2023-03-22 |
| A Clinical Study of GZR33 and GZR101 in Healthy Subjects (NCT06556641) | Gan and Lee Pharmaceuticals, USA | 2022-12-17 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4 (NCT06548815) | Gan and Lee Pharmaceuticals, USA | 2022-08-29 |
| A Study of GZR18 Injection in Chinese Obese/Overweight Patients (NCT06256536) | Gan and Lee Pharmaceuticals, USA | 2022-07-14 |
| A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult Subjects (NCT06548932) | Gan and Lee Pharmaceuticals, USA | 2022-06-30 |
| A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM) (NCT06256523) | Gan and Lee Pharmaceuticals, USA | 2022-06-29 |
| Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects (NCT05328726) | Gan and Lee Pharmaceuticals, USA | 2022-03-08 |
| A Phase I Study of GZR18 Injection in Healthy Subjects (NCT06548997) | Gan and Lee Pharmaceuticals, USA | 2021-12-02 |
| Evaluation of GLR2007 for Advanced Solid Tumors (NCT04444427) | Gan and Lee Pharmaceuticals, USA | 2020-07-15 |
| PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy Males (NCT04237129) | Gan and Lee Pharmaceuticals, USA | 2019-08-27 |
| PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients (NCT04236895) | Gan and Lee Pharmaceuticals, USA | 2018-07-10 |
| Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (NCT03371082) | Gan and Lee Pharmaceuticals, USA | 2017-10-31 |
| Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (NCT03371108) | Gan and Lee Pharmaceuticals, USA | 2017-10-31 |